Role of vitamin D in the onset, progression, and severity of multiple sclerosis

Endocrine Practice

Volumn 19, Issue 1, 2013, Pages 129-136

  Mesliniene, Sandra ^a   Ramrattan, Laurie ^a   Giddings, Stanley ^a   Sheikh Ali, Mae ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; 7 DEHYDROCHOLESTEROL; B CELL ACTIVATING FACTOR; CALCITRIOL; COD LIVER OIL; COLECALCIFEROL; EPSTEIN BARR VIRUS ANTIGEN 1; ERGOCALCIFEROL; GADOLINIUM; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 5; OMEGA 3 FATTY ACID; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D; VITAMIN D RECEPTOR; VITAMIN;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALOMYELITIS; BLOOD BRAIN BARRIER; BRAIN DAMAGE; CELL MATURATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DENDRITIC CELL; DISABILITY; DISEASE COURSE; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; EXPANDED DISABILITY STATUS SCALE; FOLLOW UP; HUMAN; HYPERCALCEMIA; IMMUNOCOMPETENT CELL; INFLAMMATION; INTERVENTION STUDY; LIFESTYLE; MACROPHAGE; MEDICAL SUBJECT HEADINGS; MEDLINE; MULTIPLE SCLEROSIS; NONHUMAN; OBSERVATIONAL STUDY; PATHOGENESIS; POPULATION SIZE; PUBLICATION; RECURRENCE RISK; REVIEW; RISK FACTOR; TH1 CELL; TH2 CELL; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; DIET SUPPLEMENTATION; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

DIETARY SUPPLEMENTS; DISEASE PROGRESSION; HUMANS; MULTIPLE SCLEROSIS; SEVERITY OF ILLNESS INDEX; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84881488958     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP12152.RA     Document Type: Review

References (46)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502-1517.
2. Holick MF. Vitamin D: Extraskeletal health. Endocrinol Metab Clin North Am. 2010;39:381-400.
3. Hewison M. Vitamin D and the intracrinology of innate immunity. Mol Cell Endocrinol. 2010;321:103-111.
4. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005;289:F8-28.
5. Hewison M, Freeman L, Hughes SV, et al. Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J Immunol. 2003;170:5382-5390. (Pubitemid 36617823)
6. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O'Garra A. 1alpha,25-dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol. 2001;167:4974-4980. (Pubitemid 33009728)
7. Daniel C, Sartory NA, Zahn N, Radeke HH, Stein JM. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther. 2008;324:23-33. (Pubitemid 350294165)
8. Hewison M. Vitamin D and the immune system: New perspectives on an old theme. Endocrinol Metab Clin North Am. 2010;39:365-379.
9. Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol. 2007;179:1634-1647.
10. Disanto G, Meier U, Giovannoni G, Ramagopalan SV. Vitamin D: A link between epstein-barr virus and multiple sclerosis development? Expert Rev Neurother. 2011;11:1221-1224.
11. Lemire JM, Archer DC. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest. 1991;87:1103-1107.
12. Cantorna MT, Hayes CE, DeLuca HF. 1,25-dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA. 1996;93:7861-7864. (Pubitemid 26277129)
13. Spach KM, Hayes CE. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J Immunol. 2005;175:4119-4126. (Pubitemid 41292076)
14. Chang JH, Cha HR, Lee DS, Seo KY, Kweon MN. 1,25-dihydroxyvitamin D3 inhibits the differentiation and migration of T(H)17 cells to protect against experimental autoimmune encephalomyelitis. PLoS One. 2010;5:e12925.
15. Lysandropoulos AP, Jaquiery E, Jilek S, Pantaleo G, Schluep M, Du Pasquier RA. Vitamin D has a direct immunomodulatory effect on CD8+ T cells of patients with early multiple sclerosis and healthy control subjects. J Neuroimmunol. 2011;233:240-244.
16. Lossius A, Vartdal F, Holmoy T. Vitamin D sensitive EBNA-1 specific T cells in the cerebrospinal fluid of patients with multiple sclerosis. J Neuroimmunol. 2011;15;240-241:87-96.
17. Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol. 2010;9:599-612.
18. Lucas RM, Ponsonby AL, Dear K, et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology. 2011;76:540-548.
19. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296:2832-2838. (Pubitemid 44969183)
20. Mirzaei F, Michels KB, Munger K, et al. Gestational vitamin D and the risk of multiple sclerosis in offspring. Ann Neurol. 2011;70:30-40.
21. Munger KL, Chitnis T, Frazier AL, Giovannucci E, Spiegelman D, Ascherio A. Dietary intake of vitamin D during adolescence and risk of multiple sclerosis. J Neurol. 2011;258:479-485.
22. Pierrot-Deseilligny C. Clinical implications of a possible role of vitamin D in multiple sclerosis. J Neurol. 2009;256:1468-1479.
23. Soilu-Hanninen M, Laaksonen M, Laitinen I, Eralinna JP, Lilius EM, Mononen I. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2008;79:152-157. (Pubitemid 351236545)
24. Nieves J, Cosman F, Herbert J, Shen V, Lindsay R. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology. 1994;44:1687-1692. (Pubitemid 24286648)
25. McDowell TY, Amr S, Culpepper WJ, et al. Sun exposure, vitamin D intake and progression to disability among veterans with progressive multiple sclerosis. Neuroepidemiology. 2011;37:52-57.
26. Soilu-Hanninen M, Airas L, Mononen I, Heikkila A, Viljanen M, Hanninen A. 25-hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler. 2005;11:266-271. (Pubitemid 40775180)
27. Disanto G, Handel AE, Morahan JM, et al. Vitamin D and multiple sclerosis hospital admissions in Scotland. QJM. 2011;104:1001-1003.
28. Neau JP, Artaud-Uriot MS, Lhomme V, et al. Vitamin D and multiple sclerosis. A prospective survey of patients of poitou-charentes area. Rev Neurol (Paris). 2011;167:317-323.
29. Weinstock-Guttman B, Zivadinov R, et al. Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. J Neurol Neurosurg Psychiatry. 2011;82:189-195.
30. Simpson S Jr, Taylor B, Blizzard L, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol. 2010;68:193-203.
31. Gelfand JM, Cree BA, McElroy J, et al. Vitamin D in African Americans with multiple sclerosis. Neurology. 2011;76:1824-1830.
32. Yildiz M, Tettenborn B, Putzki N. Vitamin D levels in swiss multiple sclerosis patients. Swiss Med Wkly. 2011;141:w13192.
33. Langer-Gould A, Huang S, Van Den Eeden SK, et al. Vitamin D, pregnancy, breastfeeding, and postpartum multiple sclerosis relapses. Arch Neurol. 2011;68:310-313.
34. Orton SM, Ramagopalan SV, Para AE, et al. Vitamin D metabolic pathway genes and risk of multiple sclerosis in canadians. J Neurol Sci. 2011;305:116-120.
35. Mahon BD, Gordon SA, Cruz J, Cosman F, Cantorna MT. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol. 2003;134:128-132. (Pubitemid 36050838)
36. Kimball S, Vieth R, Dosch HM, et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. J Clin Endocrinol Metab. 2011;96:2826-2834.
37. Mosayebi G, Ghazavi A, Ghasami K, Jand Y, Kokhaei P. Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunol Invest. 2011;40:627-639.
38. Stein MS, Liu Y, Gray OM, et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology. 2011;77:1611-1618.
39. Goldberg P, Fleming MC, Picard EH. Multiple sclerosis: Decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses. 1986;21:193-200. (Pubitemid 17201931)
40. Nordvik I, Myhr KM, Nyland H, Bjerve KS. Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol Scand. 2000;102:143-149. (Pubitemid 30645133)
41. Wingerchuk DM, Lesaux J, Rice GP, Kremenchutzky M, Ebers GC. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005;76:1294-1296. (Pubitemid 41208389)
42. Smolders J, Peelen E, Thewissen M, et al. Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS One. 2010;5:e15235.
43. Knippenberg S, Smolders J, Thewissen M, et al. Effect of vitamin D(3) supplementation on peripheral B cell differentiation and isotype switching in patients with multiple sclerosis. Mult Scler. 2011;17:1418-1423.
44. Kimball SM, Ursell MR, O'Connor P, Vieth R. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr. 2007;86:645-651. (Pubitemid 47435831)
45. Holick MF. Vitamin D Deficiency. N Engl J Med. 2007;357:266-281.
46. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911-1930.